Novo Nordisk CEO says CVS breakup has no material impact on the company
FROM THE WIRE · FINANCE.YAHOO.COM
For now, Novo Nordisk (NVO) CEO Mike Doustdar says it's business as usual for its weight-loss drug behemoth as healthcare giant CVS Health (CVS) undergoes a complicated breakup. "In some ways, I would say I don't see a material impact for us other than now we have to of course…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe CEO sees limited impact from the CVS separation on formulary negotiations for Novo's drugs.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01CEO Mike Doustdar says he sees no material impact.
- 02CVS Health announced plans to split its $117 billion healthcare group into two listed businesses.
- 03The separation unwinds the vertical integration following the 2018 acquisition of Aetna.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
CVS Health Corp.80.55 USD+0.43%today -11.89%Neutral Novo Nordisk A/S42.78 USD-0.41%today +6.44%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets